Company / Shareholders' Equity
Amylyx Pharmaceuticals, Inc. Shareholders' Equity History
FY2021-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Shareholders' Equity
$305.3M
FY2025
5-year range
-$151.2M / $433.4M
FY2021-FY2025
Trend
+85.3%
vs FY2024
Sector context
#131 of 213
Health Care
What the data says
At $305M, Amylyx Pharmaceuticals, Inc.'s shareholders' equity ranks #131 of 213 in the Health Care sector. Declined from $433M to $305M over the past 2 years.
Based on SEC 10-K filings.
$305M in FY2025 with a 3-year CAGR of -3.6%.
Declined from $433M to $305M over the past 2 years.
Health Care sector context is included.
Shareholders' Equity over time
Growth rates
- 3-Year CAGR
- -3.6%
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Sector benchmark
#131 of 213 in Health CareTop 62% of 213This company $305.3M Sector average $2.5B
▼
-88.0% below sector average
Key checks
Key Insights
- 3-year CAGR of -3.6%, indicating a declining trend.
- In FY2025, shareholders' equity increased 85.3% year-over-year.
- Ranks #131 out of 213 companies in the Health Care sector.
- Peak shareholders' equity was recorded in FY2023.
Company context
Key Data Points
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Shareholders' EquityValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $305.3M | +85.3% |
| FY2024 | $164.8M | -62.0% |
| FY2023 | $433.4M | +27.3% |
| FY2022 | $340.6M | +325.3% |
| FY2021 | -$151.2M | - |
As of FY2025 · SEC 10-K · Updated Jul 2, 2026